Accelerating Cancer Immunotherapy: Optimization of an EGFRvIII-Based Cancer Vaccine via Computationally-aided Analysis of Proteasome Processing for Improved Glioblastoma Prognosis
ISEF · 2016 First Award
Overview
Cancer vaccines are a revolutionary field of cancer therapeutics that aim to utilize the body’s natural defenses to treat cancer. Through this research, I optimized an effective anti-cancer vaccine based on the EGFRvIII mutation in glioblastoma by computationally and experimentally evaluating survival data with optimal proteasome processing and MHC antigen presence. Mass Spectrometry (MS) was conducted on amino acid-substituted variations of the LEEKKGNYVVTDHC (LEEK) peptide that were fed to the human proteasome, and peptides bound to MHC on U87 glioma cell lines were evaluated for immunogenic matches. By analyzing existing mouse survival and tumor volume data, I noted that tyrosine and alanine substitutions of the peptide vaccine performed consistently better than other variants. Several repetitions of MS demonstrated large amounts of processing of tyrosine and alanine-substituted peptides at 2606 Da and 973 Da, which were then fully characterized using the graphical and computational methods I created. A peptide of identical molecular weight was detected in the tumor-associated antigen population, bound to EGFRvIII+ U87 MHC. Furthermore, 973 Da processed fragment, as validated computationally and biologically, was found to be present in processed fragments of effective variations, but not present in ineffective variations. I also demonstrated the relationship between the production of key intermediate fragments by antigen presenting cells and survival data, leading to the discovery of the most efficacious vaccines. A successfully optimized EGFRvIII-based cancer vaccine can potentially be applied to improve long-term prognosis for glioblastoma patients. Furthermore, this method of analysis can be used to improve other biomarker-based immunotherapeutic treatments.
Awards (1)
- First Award of $5,000 $5,000
Competition history
- ISEF 2016
Resources
Related projects
ISEF · 2015
Novel Design and Optimization of an EGFRvIII-based Cancer Peptide Vaccine
ISEF · 2019
Tuning Vaccine Physical Properties to Improve Anti-tumor Response Using Polyplexes
ISEF · 2018
Designing a Modified HAC-PD-1 to Antagonize PD-L2 for the Improvement of Cancer Immunotherapy
ISEF · 2026
Protein Assassins: Screening for Improved Degraders to Reverse Tumor Immortality
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair